BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Clinical trial NCT03943472 · UNKNOWN
Trial details
- NCT number
- NCT03943472
- Sponsor
- Hrain Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-08
- Primary completion
- 2021-11-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.